PRV Bill Heads To Obama; Groups Point To 'Cures' For Long-Term Solution

As a short-term reauthorization of FDA's pediatric priority review voucher program heads to the president, patient advocacy groups and a key senator are holding up 21st Century Cures as a way to achieve a longer solution. However, advocacy groups say the two-year pediatric voucher extension in the pending House-passed Cures bill still isn't long enough to incentivize drug development and instead point to a five-year expansion passed as part of the Senate-companion package as a workable solution. The House on...